What is the clinical evidence from this study?

Study design: Review. Population: Obesity-associated renal disease.

What does this research mean for the field?

Obesity is associated with renal complications including proteinuria and focal glomerulosclerosis, which can progress to end-stage renal disease but may be mitigated by early weight reduction and angiotensin-converting enzyme inhibition. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the clinical characteristics, pathological mechanisms, and management strategies of obesity-associated proteinuria and renal disease.

May 1, 2002Current Opinion in Nephrology & Hypertension

Obesity and renal disease

View Full Paper

Ask AI

Bookmark

Key result

Obesity is associated with renal complications including proteinuria and focal glomerulosclerosis, which may be mitigated by early weight reduction and angiotensin-converting enzyme inhibition.

Population

Patients with obesity and obesity-associated proteinuria

Design

Review

Authors

RARaymond D. AdelmanSutter Medical Center

Discussion

Member takes

Implication

Supports early weight reduction plus ACE inhibition for obesity-related proteinuria; leaves open need for randomized confirmation.

Key Points

To review the clinical characteristics, pathological mechanisms, and management strategies of obesity-associated proteinuria and renal disease.
Narrative review examining clinical presentations, renal biopsy findings, and pathophysiological pathways linking severe obesity to kidney dysfunction.
Evaluation of metabolic, hemodynamic, and fibrogenic mediators, as well as therapeutic options including pharmacological inhibition and weight loss.
Obesity-related nephropathy presents histologically as glomerulomegaly and focal glomerulosclerosis, leading to progressive proteinuria and risk of end-stage renal disease despite often normal serum albumin and cholesterol.
Pathophysiologic drivers involve glomerular hyperfiltration, elevated renal venous pressure, and heightened synthesis of fibrogenic mediators such as angiotensin II, leptin, insulin, and transforming growth factor-beta1.
Angiotensin-converting enzyme inhibitors offer temporary reduction in proteinuria, but early weight loss serves as the definitive intervention to halt disease progression.

Structured PICO

Population

Patients with obesity and obesity-associated proteinuria

Intervention

Weight reduction and angiotensin-converting enzyme (ACE) inhibition

Obesity can lead to proteinuria and end-stage renal disease, with weight reduction being the primary recommended therapeutic approach.

Cite This Study

Raymond D. Adelman (2002) conducted a review in Obesity-associated renal disease. Obesity is associated with renal complications including proteinuria and focal glomerulosclerosis, which may be mitigated by early weight reduction and angiotensin-converting enzyme inhibition.

synapsesocial.com/papers/6a1d9e6633e2df9c962fcaeb https://doi.org/10.1097/00041552-200205000-00010

View Full Paper

Ask AI

Bookmark

Obesity and renal disease

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Obesity and renal disease

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider